Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: News Direct

--News Direct--

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/immunic-gets-a-positive-surprise-from-lead-asset-trial-619463718

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.71
+3.56 (1.77%)
AAPL  263.92
+0.04 (0.02%)
AMD  199.14
-3.94 (-1.94%)
BAC  53.24
+0.50 (0.95%)
GOOG  303.05
+0.23 (0.08%)
META  638.46
-0.83 (-0.13%)
MSFT  399.67
+2.81 (0.71%)
NVDA  187.81
+2.84 (1.54%)
ORCL  155.93
+1.96 (1.27%)
TSLA  410.71
+0.08 (0.02%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.